TransMedics Q2 revenue up 151% to $20.5M, raises 2022 guidance to $67M-$75M

TransMedics Group, Inc.

2022-Q2 EPS reported -$0.79 revenue$36,401,000

Net revenue $20.5M in Q2 2022 vs $8.2M a year ago (+151%); gross margin improved to 70% from 68%.
Net loss of $11.5M vs $10.7M in Q2 2021; operating expenses rose to $24.1M from $15.5M.
Entered $60M five-year loan with CIBC, replacing $35M OrbiMed facility; netted $23M cash.
Full-year 2022 revenue guidance raised to $67M-$75M (prior $59M-$65M), representing 121%-148% YoY growth.
National OCS Program drove 84% of US revenue; integrated OCS Heart DCD into NOP.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.